Skip to main content
SpringerLink
Log in

Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background

Meropenem is an anti-Gram-negative antimicrobial, the time-dependent activity of which may be maximized through administration by continuous infusion.

Objectives

The objectives of this study were to characterize the pharmacokinetics of continuous infusion meropenem in relation to body size and Cockcroft–Gault estimated creatinine clearance (CLCR) in overweight and obese patients with stable and unstable kidney function with the intent of creating a nomogram for optimal dosing.

Patients and Methods

Patients from a single institution with a body mass index ≥25 kg/m2 receiving meropenem by continuous infusion with measurement of meropenem steady-state concentrations (C ss) were identified. Individual Bayesian estimates of meropenem volume of distribution of the central compartment (V c) and clearance (CL) were calculated and relationships to body size descriptors and CLCR estimated using these body size descriptors were defined by regression. Kidney function stability was defined based on median absolute deviation, stratification by the ratio of maximum to minimum serum creatinine (SCr) and individual patient-level regression of SCr over time. The influence of kidney function stability on meropenem CL estimation by CLCR was tested.

Results

A total of 375 patients (77.9 % male) with 846 C ss values (62.4 % of patients with ≥2 measurements) were identified. The median daily dose of meropenem and frequency of infusion bag changes were 2000 mg/day and four times per day, respectively. The meropenem C ss values were ≥16, ≥8, ≥4, and ≥2 mg/L for 41.1, 76.1, 97.4, and 99.9 % of observations, respectively. The median (range) age, weight, and BMI were 66 (24–90) years, 90 (70–250) kg, and 30.8 (25.1–81.6) kg/m2, respectively. The mean [standard deviation (SD)] serum creatinine at baseline was 1.57 (1.37) mg/dL. The mean (SD) V c was 28.1 (1.36) L and not related to body size, while CL was 8.85 (6.40) L/h and best related to CLCR estimated using adjusted body weight (ABW). The meropenem CL to CLCR relationship was not significantly impacted by the presence or absence of kidney function stability. The user-friendly dosing nomogram based on CLCR estimated using ABW showed that optimal drug exposure [Css ≥ minimum inhibitory concentration (MIC)] may be obtained even against multi-drug resistant (MDR) pathogens when considering dosages up to 1250 mg every 6 h by continuous infusion.

Conclusions

Meropenem CL is best estimated using CLCR with ABW in patients with a BMI ≥25 kg/m2 and this relationship is not altered by unstable kidney function. Application of our dosing nomogram may improve the care of overweight and obese patients with severe MDR Gram-negative infections treated with meropenem by continuous infusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81.

    Article  PubMed  Google Scholar 

  2. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87.

    Article  CAS  PubMed  Google Scholar 

  3. Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol. 2013;33(1):14–22.

    Article  CAS  PubMed  Google Scholar 

  4. Hites M, Taccone FS, Wolff F, et al. Broad-spectrum beta-lactams in obese non-critically ill patients. Nutr Diabetes. 2014;4:e119.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis. 2010;17(5):e53–62.

    Article  PubMed  Google Scholar 

  6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.

    Article  CAS  PubMed  Google Scholar 

  7. Pea F, Viale P, Cojutti P, et al. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother. 2012;56(12):6343–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. MERREM® IV (meropenem for injection) [product label]. Wilmington: Astra Zeneca Pharmaceuticals LP. 2006. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050706s022lbl.pdf. Accessed 13 Dec 2014.

  9. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2012;56(6):2795–805.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother. 2005;49(5):1881–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Zavascki AP, Carvalhaes CG, Picao RC, et al. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther. 2010;8(1):71–93.

    Article  CAS  PubMed  Google Scholar 

  12. Cohen J. Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients. J Antimicrob Chemother. 2013;68(3):490–1.

    Article  CAS  PubMed  Google Scholar 

  13. Franceschi L, Cojutti P, Baraldo M, et al. Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. Ther Drug Monit. 2014;36(5):674–6.

    Article  CAS  PubMed  Google Scholar 

  14. Manning L, Wright C, Ingram PR, et al. Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability. PLoS One. 2014;9(7):e102023.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Carlier M, Stove V, Verstraete AG, et al. Stability of generic brands of meropenem reconstituted in isotonic saline. Minerva Anestesiol. 2015;81(3):283–7.

    CAS  PubMed  Google Scholar 

  16. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1–16.

    Article  CAS  PubMed  Google Scholar 

  17. Li C, Du X, Kuti JL, et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007;51(5):1725–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Tam VH, Nikolaou M. A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Comput Biol. 2011;7(1):e1001043.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Tam VH, Schilling AN, Neshat S, et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49(12):4920–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.

    CAS  PubMed  Google Scholar 

  21. Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. Ann Pharmacother. 2000;34(9):1066–9.

    Article  CAS  PubMed  Google Scholar 

  22. Bauer LA, Edwards WA, Dellinger EP, et al. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643–7.

    Article  CAS  PubMed  Google Scholar 

  23. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.

    Article  PubMed  Google Scholar 

  24. National Heart, Lung, and Blood Institute. Classification of overweight and obesity by BMI, waist circumference, and associated disease risks. https://www.nhlbi.nih.gov/health/educational/lose_wt/BMI/bmi_dis.htm. Accessed 13 Mar 2015.

  25. Cheatham SC, Fleming MR, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. J Clin Pharmacol. 2014;54(3):324–30.

    Article  CAS  PubMed  Google Scholar 

  26. Roberts JA, Ulldemolins M, Roberts MS, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36(4):332–9.

    Article  CAS  PubMed  Google Scholar 

  27. Kays MB, Fleming MR, Cheatham SC, et al. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients. Ann Pharmacother. 2014;48(2):178–86.

    Article  CAS  PubMed  Google Scholar 

  28. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17(8):1135–41.

    Article  CAS  PubMed  Google Scholar 

  29. Pea F, Cojutti P, Merelli M, et al. Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site. Int J Antimicrob Agents. 2014;44(6):570–1.

    Article  CAS  PubMed  Google Scholar 

  30. Hsu AJ, Tamma PD. Treatment of multidrug-resistant Gram-negative infections in children. Clin Infect Dis. 2014;58(10):1439–48.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No external funding was used in the conduct of this study. Federico Pea has received funds for speaking at symposia organized on behalf of Astra Zeneca. Manjunath Pai and Piergiorgio Cojutti have no potential conflicts of interest that might be relevant to the contents of this manuscript.

Author information

Authors and Affiliations

  1. Albany College of Pharmacy and Health Sciences, Albany, NY, USA

    Manjunath P. Pai

  2. Institute of Clinical Pharmacology, Santa Maria della Misericordia University Hospital, Udine, Italy

    Piergiorgio Cojutti & Federico Pea

  3. Department of Experimental and Clinical Medical Sciences, University of Udine, Udine, Italy

    Piergiorgio Cojutti & Federico Pea

Authors
  1. Manjunath P. Pai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Piergiorgio Cojutti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Federico Pea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Federico Pea.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pai, M.P., Cojutti, P. & Pea, F. Pharmacokinetics and Pharmacodynamics of Continuous Infusion Meropenem in Overweight, Obese, and Morbidly Obese Patients with Stable and Unstable Kidney Function: A Step Toward Dose Optimization for the Treatment of Severe Gram-Negative Bacterial Infections. Clin Pharmacokinet 54, 933–941 (2015). https://doi.org/10.1007/s40262-015-0266-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-015-0266-2

Keywords

Search

Navigation